Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes is defined by its association with hyperglycemia-specific microvascular complications; however, it also imparts a two- to fourfold risk of cardiovascular disease (CVD). Although microvascular complications can lead to significant morbidity and premature mortality, by far the greatest cause of death in people with diabetes is CVD. Results from randomized controlled trials have demonstrated conclusively that the risk of microvascular complications can be reduced by intensive glycemic control in patients with type 1 (1,2) and type 2 diabetes (3–5). In the Diabetes Control and Complications Trial (DCCT), there was an ∼60% reduction in development or progression of diabetic retinopathy, nephropathy, and neuropathy between the intensively treated group (goal A1C <6.05%, mean achieved A1C ∼7%) and the standard group (A1C ∼9%) over an average of 6.5 years. The relationship between glucose control (as reflected by the mean on-study A1C value) and risk of complications was log-linear and extended down to the normal A1C range (<6%) with no threshold noted. In the UK Prospective Diabetes Study (UKPDS), participants newly diagnosed with type 2 diabetes were followed for 10 years, and intensive control (median A1C 7.0%) was found to reduce the overall microvascular complication rate by 25% compared with conventional treatment (median A1C 7.9%). Here, too, secondary analyses showed a continuous relationship between the risk of microvascular complications and glycemia extending into the normal range of A1C, with no glycemic threshold. On the basis of these two large controlled trials, along with smaller studies and numerous epidemiologic reports, the consistent findings related to microvascular risk reduction with intensive glycemic control have led the American Diabetes Association (ADA) to recommend an A1C goal of <7% for most adults with diabetes (6), recognizing that more or less stringent goals may be appropriate for certain patients. Whereas many epidemiologic studies and meta-analyses …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, severe hypoglycemia may also be a marker of vulnerability, without any direct causal contribution to the increased mortality (72).”
From Hypoglycemia (2018) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Research works printed but not linked: 1
- Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vikek ME, Henderson WG, Huang GD: Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. In press
Cited by
Items 801–879 of 879
Role of Human Leucocyte Antigen (HLA) Class II Gene Polymorphism in Type 1 Diabetes Mellitus
Ali, B., Mahdi, W. K. M., & Mahrous, D. M. (2016) · The Egyptian Journal of Medical Microbiology · doi:10.12816/0037001
Evaluation and Management of the Newly Diagnosed Patient with Type-2 Diabetes
Miller, J. D. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2059-4_42
Trujillo, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4975-1.00012-7
Khait, A. F. A., & Rashaid, S. A. (2016) · International Journal of Mental Health & Psychiatry · doi:10.4172/2471-4372.1000129
Tratamiento de la diabetes mellitus (II). Hipoglucemiantes no insulínicos
Ampudia‐Blasco, F. J., & Perelló-Camacho, E. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.011 · Cited by 1
Krapek, K. J. (2016) · ePublications at Regis University (Regis University)
Short-term aerobic exercise training in type 2 diabetes
Kearney, M. L. (2015) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/50150
Doctor of Nursing Practice portfolio of Winnifreda E. Licaycay
Licaycay, W. E. (2009) · doi:10.6083/m43f4mkt
Wang, C., Dong, Z., Yi, Z., Ying, J., & Zhang, G. (2016) · CRC Press eBooks · doi:10.1201/9781315368511-6
Rymar, O. D., Ivanchikhin, A. N., Kozlova, V. T., Ruzaeva, Y. D., & Dolinskaya, Y. A. (2014) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2014-2-61-65
(2015) · The American Pharmacists Association eBooks · doi:10.21019/9781582122175.ch17
Distribution of Methylated Regions Within gDNA in Acute and Chronic Phases of Diabetes Mellitus
Leontovich, A. A., & Sarras, M. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_76-1
Inkretinbasierte Diabetesmedikamente: Kardiovaskuläre Sicherheit bzw. kardiovaskulärer „Benefit“
Lee-Barkey, Y., Stratmann, B., & Tschöpe, D. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0269-8
Is HbA1c still the Gold Standard for Glycemic Control?
Borz, V. (2017) · Journal of Diabetic Complications & Medicine · doi:10.4172/2475-3211.1000e103 · Cited by 1
The Effects of High Glucose Exposure on Endothelial Microparticles
Turner, M. (2017) · uO Research (University of Ottawa) · doi:10.20381/ruor-20940
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_14-1
Fall 54: Prävention – 55 Jahre, ♀, DM Typ 2, Aufnahme mit Herzinfarkt
Fischer, A., & Nawroth, P. P. (2018) · Springer eBooks · doi:10.1007/978-3-662-55972-7_54
Désordres glycémiques et complications diabétiques : physiopathologie
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00009-3
Fernández, M. A. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(18)30372-1
Lee, C. C., & Liu, S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384978-6.00057-1
Старченко, Т. Г., Koval, S. M., Yushko, K. O., Shkapo, V. L., & Miloslavsky, D. К. (2018) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2018-3-1-145-42-46
Joshi, A., Adhikari, B., Tamrakar, B. K., Puppalwar, G., Shah, A., & Jain, R. (2019) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2019.92003
Lifestyle intervention strategies for diabetes management
Tay, J., & Tay, J. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.25909/5b63b9ac0685f
Korai kombinált antidiabetikus kezelés 2-es típusú diabetesben
Winkler, G. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.18
Treatment Goals for Glycemia in Older Patients with Diabetes Mellitus
Lim, J. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.4.220
Microneedle mediated optical detection of glucose concentration in aqueous solutions
Nicholas, D. (2019) · Ulster University Research Portal (Ulster University)
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Thérapeutique des désordres glycémiques
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70868-8.50007-4
The Role of Diet in the Prevention and Treatment of Diabetes
Wylie‐Rosett, J., & Delahanty, L. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391884-0.00032-9 · Cited by 3
Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease
Garber, A. J. (2011) · Endocrine Practice · doi:10.1016/s1530-891x(20)43147-7
Vialettes, B. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.006
Anitha, B., Veena Juliette, A., & Murali, T. (2021) · Indian Journal Of Applied Research · doi:10.36106/ijar/4713706
Brown, R. (2021) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.82173 · Cited by 1
Recommendations on the Clinical Trial Programme for Diabetes Medicines
Анатольевна, П. И., Petraneva, E. V., & Goryachev, D. V. (2021) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2021-11-2-94-103
Wahedy, K. M., Bilbeisi, A. H. E., & Bakry, M. J. (2021) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2021.90526.1147 · Cited by 12
de Carvalho, L. S. F., Nogueira, A. C. C., Cintra, R. M. R., Bonilha, I., Luchiari, B., Benchimol, A. K., Couri, C. E. B., Borges, J. L., Barreto, J., & Sposito, A. C. (2021) · Research Square · doi:10.21203/rs.3.rs-983766/v1
Movement behaviours and cardiovascular risk factors in individuals living with type 1 diabetes
Wu, N. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0402599
Bilous, F. R., Donnelly, R., & DM, F. I. I. (2021) · Wiley eBooks · doi:10.1002/9781118976074.ch14
(2009) · Wiley eBooks · doi:10.1002/9781444317176.refs
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_14
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Current literature in diabetes
(2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.993
Williams, M. E., & Stanton, R. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00006-9
Sarras, M. P., & Leontovich, A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_71-1
Hudson, M., & Palermo, N. E. (2020) · Springer eBooks · doi:10.1007/978-3-319-47771-8_14
Correa, A., & Marcinkevage, J. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195317060.003.0010 · Cited by 1
Distribution of Methylated Regions Within gDNA in Acute and Chronic Phases of Diabetes Mellitus
Leontovich, A. A., & Sarras, M. P. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_76
Type 1 Diabetes Mellitus in the Inclusive School Setting: Daily and Long Term Effects on Education
Hoffman, J. C., & Osipoff, J. N. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-0034-6.ch008
Methods in Clinical Pharmacology
Rusch, L. M., & Dehn, C. A. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_28
Achievement of therapeutic targets in Mexican patients with diabetes mellitus
Lavalle-Gonzalez, F. J., Chiquete, E., de la Luz, J., Ochoa-Guzmán, A., Sánchez-Orozco, L. V., & Godínez-Gutiérrez, S. A. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.12.002 · Cited by 1
Désordres glycémiques et complications diabétiques : physiopathologie
Monnier, L., & Colette, C. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00009-9 · Cited by 1
Study of association of diabetic retinopathy with dyslipidemia in type II diabetes mellitus
Yelamanchili, P. P., Kurakula, M., Kiranmayi, P. S., & Viswanath, K. (2022) · ScienceRise Medical Science · doi:10.15587/2519-4798.2022.262185
MODERN MEANS AND APPROACHES TO TREATMENT FOR DIABETES MELLITUS TYPE 2
Kapliyeva, M. P. (2012) · Health and Ecology Issues · doi:10.51523/2708-6011.2012-9-2-4
Efficience et précision du contrôle glycémique dans le diabète : symphonie inachevée ?
Monnier, L., Halimi, S., & Colette, C. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.11.005
Rybak, V. A., Honcharov, A., & Korol, V. (2022) · ScienceRise Pharmaceutical Science · doi:10.15587/2519-4852.2022.271034
AlBurno, H. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20240118ha
Barnard-Kelly, K. D., & Holt, R. I. G. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch25 · Cited by 1
Mediators of Cardiovascular and Renal Outcomes: How Do Novel Diabetes Medications Work?
Dakroub, A. H., & Almarzooq, Z. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.033863
Cardiovascular Disease Risk and Risk Reduction Strategies in Diabetes Mellitus
Wilson, D. P., Hamilton, L., & Maki, K. C. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_14
Patient Selection, Clinical Considerations, and Intensive Diabetes Management Goals
Steenkamp, D. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407694.ch05
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Lee, W., Chen, H., Fang, C.-Y., Tsai, Y., Hsieh, Y.-Y., Chen, T., Fang, Y., Wu, P., Fang, H., & Liu, P. (2025) · Current Vascular Pharmacology · doi:10.2174/0115701611322555250219111038
Incretin integration: Charting the future of cardiovascular-kidney-metabolic health
Wang, C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001277
Kimura, K., TAKAGI, Y., Harada, M., Ueda, S., Minamisawa, M., Sonoda, K., Oiwa, A., Yazaki, Y., Sakurai, S., Tomita, T., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01822-8
Fang, Q., Shi, J., Zhang, J., Peng, Y. H., Liu, C., Wei, X., Hu, Z., Sun, L., Hong, J., Gu, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23639884
Fang, Q., Shi, J., Zhang, J., Peng, Y. H., Liu, C., Wei, X., Hu, Z., Sun, L., Hong, J., Gu, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23639881
Fang, Q., Shi, J., Zhang, J., Peng, Y. H., Liu, C., Wei, X., Hu, Z., Sun, L., Hong, J., Gu, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23639878
Jiang, L., Shi, K., Guo, Y., Ren, Y., Li, Z.-L., Xia, C.-C., Li, L., Liu, X., Xie, L.-J., Gao, Y., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12262151
Fang, Q., Shi, J., Zhang, J., Peng, Y. H., Liu, C., Wei, X., Hu, Z., Sun, L., Hong, J., Gu, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23639887
Ningappa, A., & Nagaraj, M. (2025) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_768_24
Evans, W. R., Grosek, N. C., Wisen, W. P., Oruganti, L., Ageeli, R. Y., Mostany, R., & Katakam, P. V. G. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115605
Wagh, P., Choudhari, V. P., More, C., Bobade, C., & Choudhari, G. B. (2026) · Next research. · doi:10.1016/j.nexres.2026.101489
Lahoud, N. (2015) · theses.fr (ABES) · doi:10.70675/2a5833a8z08b3z4bfcz8c88zd002df2ffcce · Cited by 1
Teklay, G., Tafere, H., & Niriayo, Y. L. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02332-9
Is Insulin Resistance an Adaptive Response? Clues from Nature
Sweazea, K. L. (2026) · Physiology · doi:10.1152/physiol.00059.2025
Lee, C. C., & Liu, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00086-x
Bruggeman, B. S., Jacobsen, L. M., Foster, T. P., & Winter, W. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-21725-8.00005-6
Takeda, Y., Ozawa, T., Ikoma, M., Shimada, K., Saito, R., Nakagawa, A., Sawamura, T., & Kumashiro, N. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01920-1
Taylor, M. J. (2013) · Scholarship@Western (Western University)
Metadata
- Authors
- Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S.
- Affiliations
- University of Miami (US)
- Park Nicollet Clinic (US)
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of California, San Francisco (US)
- University of Bristol (GB)
- American Diabetes Association (US)
- Saint Luke's Hospital (US)
- Carl T. Hayden Veterans Affairs Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-01-01
- Volume
- 32
- Issue
- 1
- Pages
- 187-192
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2606812
- OpenAlex
- W2181092548
- Cited by
- 881
- References
- 22
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 13 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 37 · 2019: 40 · 2018: 43 · 2017: 46 · 2016: 53 · 2015: 70 · 2014: 56 · 2013: 68 · 2012: 101
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- Sanofi
- Edwards Lifesciences
- Osiris Therapeutics
- Insulet Corporation
- MannKind Corporation
- Halozyme
- Dexcom
- Tandem Diabetes Care
- Daiichi-Sankyo
- Novo Nordisk
- Pfizer Pharmaceuticals
- Daiichi Sankyo Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, cardiovascular events, type 1 diabetes, type 2 diabetes, microvascular complications, HbA1c targets, ACCORD trial, ADVANCE trial, Diabetes Control and Complications Trial, UKPDS, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cardiovascular risk
- MeSH terms
- Adult, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Homeostasis, Humans, Hyperglycemia, Middle Aged, Risk Factors, Sensitivity and Specificity, Randomized Controlled Trials as Topic, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.